XTRA:SY1Chemicals
Symrise (XTRA:SY1) Valuation Check After €295 Million Impairment Charges Announcement
Symrise (XTRA:SY1) has put investors on alert after flagging impairment charges of about €295 million for the fourth quarter of 2025, tied to its terpenes business and its stake in Swedencare AB.
See our latest analysis for Symrise.
At a share price of €72.58, Symrise has seen a 6.1% 1 month share price return but a 90 day share price decline of 11.3%, while the 1 year total shareholder return of 25.8% loss points to fading longer term momentum that the latest impairment news is likely...